Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Mosaic Immunoengineering (OP:CPMV)

0.3140 UNCHANGED
Streaming Delayed Price Updated: 1:43 PM EST, Feb 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Mosaic Immunoengineering

News headline image
Mosaic ImmunoEngineering Agrees to Acquire Clinical Necroptosis Cancer Therapy Assets from Oncotelic Therapeutics, Inc.
Via ACCESSWIRE
News headline image
Mosaic ImmunoEngineering Announces Issuance of U.S. Patent Covering Cancer Treatment with Its Lead Immuno-Oncology Candidate MIE-101
Via ACCESSWIRE
News headline image
UPDATE: Mosaic ImmunoEngineering's Academic Collaborators Awarded Grants Totaling $4.3 Million from NCI Focused on the Company's Novel Immuno-Oncology Platform
Via ACCESSWIRE
News headline image
Mosaic ImmunoEngineering’s Academic Collaborators Awarded Grants Totaling $4.3 Million from NCI Focused on the Company’s Novel Immuno-Oncology Plat-form
Via ACCESSWIRE
News headline image
Mosaic ImmunoEngineering Announces Completion of Exclusive Technology License Agreement with Case Western Reserve University
Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence. 
From Mosaic ImmunoEngineering Inc.
Via AccessWire
Topics Intellectual Property
News headline image
Newly Published Data Further Support Mosaic ImmunoEngineering’s Lead Immuno-Oncology Candidate MIE-101 in Combination with OX40 Checkpoint Treatment in Melanoma
- Broad, durable, and systemic anti-tumor immunity observed using inCPMV with OX40 agonist antibodies - Intratumoral inCPMV administration in combination with systemic anti-OX40 controlled the... 
From Mosaic ImmunoEngineering Inc.
Via AccessWire
News headline image
Mosaic ImmunoEngineering's Lead Immuno-Oncology Candidate MIE-101 Highlighted in Keynote Presentation
- Nanoparticle technology shown to be effective in transforming immunologically "cold" tumors to "hot" - - Data presented support durable antitumor activity - NOVATO, CA / ACCESSWIRE / November 1, 2021... 
From Mosaic ImmunoEngineering Inc.
Via AccessWire
News headline image
Mosaic ImmunoEngineering Announces Upcoming Presentation at the 23rd Annual SoCalBio Conference
Presentation to highlight Mosaic's naturally-derived immuno-oncology candidate, MIE-101 Intratumoral administration of MIE-101 activates immune cells to initiate potent, systemic and durable antitumor... 
From Mosaic ImmunoEngineering Inc.
Via AccessWire
News headline image
Spotlight Presentation at the World Molecular Imaging Congress Highlights Mosaic ImmunoEngineering's Immuno-Oncology and Modular Vaccine Platform Candidates
- Presentation detailed the Company's COVID-19 vaccine candidates that generated antibodies that neutralized SARS-CoV-2 infection of human cells - Vaccine candidates hold potential for rapid response... 
From Mosaic ImmunoEngineering Inc.
Via AccessWire
News headline image
Mosaic ImmunoEngineering Expands Immuno-Oncology Platform Through New Technology Licensing Agreement with the University of California San Diego
- Nanoparticle-based technology complements the company's intratumoral technology platform - NOVATO, CA / ACCESSWIRE / October 6, 2021 / Mosaic ImmunoEngineering, Inc. ("Mosaic" or the "Company"),... 
From Mosaic ImmunoEngineering Inc.
Via AccessWire
News headline image
Upcoming Presentation at the World Molecular Imaging Congress to Highlight Mosaic ImmunoEngineering’s Lead Immuno-Oncology and Modular Vaccine Platform COVID-19 Vaccine Candidates
NOVATO, CA / ACCESSWIRE / October 1, 2021 / Mosaic ImmunoEngineering Inc. ("Mosaic" or the "Company"), (OTCQB:CPMV), a development-stage biotechnology company focused on bridging immunology and... 
From Mosaic ImmunoEngineering Inc.
Via AccessWire
News headline image
Mosaic ImmunoEngineering Announces Keynote Presentation Highlighting its Modular Vaccine Platform Delivery Technology
- Presentation highlighted potential of polymer-based delivery system for slow-release of vaccines that potentially require no booster shots - - Delivery system is transportation and storage friendly... 
From Mosaic ImmunoEngineering Inc.
Via AccessWire
News headline image
Mosaic ImmunoEngineering Announces Publication of Data Supporting the Potential of Its SARS-CoV-2 Vaccine Candidates under its Modular Vaccine Platform
Vaccine candidates triggered high production of neutralizing antibodies against SARS-CoV-2 and SARS-CoV-1 in preclinical studies Epitopes used in the vaccine candidates are located in regions that are... 
From Mosaic ImmunoEngineering Inc.
Via AccessWire
News headline image
Mosaic ImmunoEngineering Expands Its Modular Vaccine Platform (MVP) Through New Technology Licensing Agreement with the University of California San Diego
- Licensed Candidates Hold Potential to Address Emerging SARS-CoV-2 and other Infectious Diseases Including Human and Veterinary Applications - - Data Supporting the Potential of Lead Vaccine... 
From Mosaic ImmunoEngineering Inc.
Via AccessWire
News headline image
Newly Published Preclinical Data Highlight Broad Immune Activation of Mosaic ImmunoEngineering’s Lead Intratumoral Immunotherapy Candidate, MIE-101
- Results Demonstrate Innate Immune System Activation Through Stimulation of Three Toll-Like Receptors (TLRs 2,4,7) - - MIE-101 Therapy Reduced Tumor Growth by 80% Compared to Tumors Treated with... 
From Mosaic ImmunoEngineering Inc.
Via AccessWire
News headline image
Mosaic ImmunoEngineering Submits Application for Nasdaq Uplisting
NOVATO, CA / ACCESSWIRE / June 28, 2021 / Mosaic ImmunoEngineering Inc. ("Mosaic" or the "Company"), (OTCQB:CPMV), a development-stage biotechnology company focused onimmunotherapies to treat and... 
From Mosaic ImmunoEngineering Inc.
Via AccessWire
News headline image
Mosaic ImmunoEngineering Inc. Elects Biotechnology Industry Veteran Robert A. Baffi, Ph.D. to Its Board of Directors
Experience in the Development of Biotechnology and Viral Based Therapeutics Will Help Enhance the Development of the Company's Pipeline NOVATO, CA / ACCESSWIRE / June 15, 2021 / Mosaic... 
From Mosaic ImmunoEngineering Inc.
Via AccessWire
Topics Intellectual Property
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.